
Feb 18 (Reuters) - BASILEA PHARMACEUTICA AG BSLN.S:
OUTLOOK 2025: TOTAL REVENUE IS EXPECTED TO INCREASE BY 5.5% TO CHF 220 MILLION DRIVEN BY AN INCREASE IN BARDA AND CARB-X REIMBURSEMENTS
OUTLOOK 2025: MILESTONE AND UPFRONT PAYMENTS IN 2025 ARE EXPECTED TO BE IN AVERAGE RANGE OF LAST FEW YEARS OF AROUND CHF 35 MILLION
OUTLOOK 2025: EXPECT TO MAINTAIN HIGH OPERATING PROFIT LEVEL OF 2024
OUTLOOK 2025: 12% INCOME TAX RATE WILL BE REFLECTED IN 2025 NET PROFIT
AFTER SERVING ON BOARD OF DIRECTORS FOR 14 YEARS, DOMENICO SCALA HAS DECIDED NOT TO STAND FOR RE-ELECTION
BOARD HAS NOMINATED STEPHAN SCHINDLER FOR ELECTION AS A NEW BOARD MEMBER AND CHAIRMAN
Source text: ID:nGNXbB945K
Further company coverage: BSLN.S